share_log

Earnings Call Summary | Nutex Health(NUTX.US) Q1 2024 Earnings Conference

Earnings Call Summary | Nutex Health(NUTX.US) Q1 2024 Earnings Conference

業績電話會議摘要 | Nutex Health (NUTX.US) 2024 年第一季度業績會議
moomoo AI ·  05/10 20:13  · 電話會議

The following is a summary of the Nutex Health (NUTX) Q1 2024 Earnings Call Transcript:

以下是Nutex Health(NUTX)2024年第一季度業績電話會議記錄的摘要:

Financial Performance:

財務業績:

  • Nutex Health's total revenue increased by 20% to $67.5 million for Q1 2024. Gross profit for the same period saw a growth of 113%.

  • Revenue for mature hospitals saw a growth of 6.7% for Q1 2024 against the same period last year.

  • The population health division's revenue grew by 5.4%.

  • The net loss was reduced drastically in Q1 2024 to -$364,000 from -$5.1 million in Q1 2023.

  • Cash and cash equivalents increased to $30 million by March 31, 2024.

  • 2024年第一季度,Nutex Health的總收入增長了20%,達到6,750萬美元。同期毛利增長了113%。

  • 2024年第一季度成熟醫院的收入與去年同期相比增長了6.7%。

  • 人口健康部門的收入增長了5.4%。

  • 淨虧損從2023年第一季度的-510萬美元大幅減少至2024年第一季度的-36.4萬美元。

  • 到2024年3月31日,現金和現金等價物增加到3000萬美元。

Business Progress:

業務進展:

  • Nutex Health opened four new hospitals in 2023, contributing to the system-wide increase in ER volumes by 21%.

  • There was a significant increase of 78% in the number of Medicare Advantage lives quarter-over-quarter.

  • The company is planning to open four more hospitals in 2024 subject to certain financial metrics and continues to push cost-cutting measures.

  • Revenue per patient, collections, and managing the impact of the No Surprises Act remain areas of focus.

  • The population health division continues to experience profitability and growth in Medicare Advantage lives, and has introduced new Independent Practice Associations (IPAs) in various regions.

  • Nutex Health 在 2023 年開設了四家新醫院,使全系統急診量增長了 21%。

  • Medicare Advantage的壽命同比大幅增長了78%。

  • 該公司計劃在2024年再開設四家醫院,但須遵守某些財務指標,並將繼續推動削減成本的措施。

  • 每位患者的收入、收款和管理《無意外法》的影響仍然是重點領域。

  • 人口健康部門在Medicare Advantage壽命方面繼續實現盈利和增長,並在各個地區推出了新的獨立執業協會(IPA)。

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論